Conference Coverage

Paravalvular Regurgitation Shown Major TAVR Limitation


 

FROM THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF CARDIOLOGY

The PARTNER trial used the SAPIEN Heart Valve System marketed by Edwards Lifesciences. The trial was sponsored by Edwards. Concurrent with Dr. Kodali’s report at the meeting, the results he presented appeared online (N. Engl. J. Med. 2012, March 26;366 [doi:10.1056/NEJMoa1200384]).

The PARTNER trial was sponsored by Edwards Lifesciences. Dr. Cribier said that he is a consultant to Edwards Lifesciences. Dr. Kodali said that he has been a consultant to Edwards Lifesciences, Medtronic, and St. Jude Medical, that he serves on an advisory board for Paieon Medical, and that he owns stock in Thubrikar Aortic Valve. Dr. Guyton said that he had no disclosures.

*Correction, 4/3/2012: An earlier version of this story mischaracterized the findings.

Pages

Recommended Reading

IVC Filter Perforations Are Often Asymptomatic
MDedge Cardiology
CAS, CEA Evaluated for Contralateral Occlusion
MDedge Cardiology
Everlolimus-Eluting Coronary Stents Notch Major Thrombosis Victory
MDedge Cardiology
CoreValve Excels in 'Real-World' Study
MDedge Cardiology
Four Common Comorbidities Hike Risk of Late Post-TAVI Death
MDedge Cardiology
Prasugrel Bests Double-Dose Clopidogrel in Clopidogrel Nonresponders
MDedge Cardiology
Elective Angioplasty Safe at Hospitals Without Surgical Backup
MDedge Cardiology
Intracoronary Abciximab Reduces Size of Large Myocardial Infarcts
MDedge Cardiology
Cilostazol Matches Double-Dose Clopidogrel Following PCI
MDedge Cardiology
CORONARY Trial Fails to Show Superiority of Off-Pump CABG
MDedge Cardiology